Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

Last updated: May 6, 2025
Sponsor: Richmond Research Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Primary Biliary Cholangitis

Treatment

Bioimpedence Vector Analysis

Clinical Study ID

NCT04873258
C19030
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A generic screening study to establish structural and/or functional baselines of specific organs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informedconsent.

  2. Willingness and ability to provide written, personally signed, and dated informedconsent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelinesand applicable regulations.

  3. An understanding, ability and willingness to fully comply with project proceduresand restrictions.

For PART B only:

  1. With a known history of MASLD as evidenced either of:

  2. GP diagnosis on HCF

  3. Documented Fibroscan or liver US demonstrating MASLD

Exclusion

Exclusion Criteria:

  1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic,viral hepatitis or other)

  2. Any other significant previous liver pathology (liver malignancy, portalhypertension, infiltrative liver disease)

  3. Alcohol consumption >30 units per week

  4. An Implanted cardiac devices

Study Design

Total Participants: 2000
Treatment Group(s): 1
Primary Treatment: Bioimpedence Vector Analysis
Phase:
Study Start date:
September 27, 2019
Estimated Completion Date:
December 31, 2027

Study Description

Fatty liver disease is a common condition (25% of the population) which can lead to liver inflammation, liver scarring and even liver cancer. Clinical trials are often performed in healthy volunteers, who may have underlying fatty liver without knowledge of it. In clinical trials fatty liver can both mean volunteers have abnormal liver tests, preventing them joining the trial, as well as more likely to have a possible liver drug reaction, causing volunteers to withdraw from a clinical trial of a new drug.

The principal objective of the study is to develop a clinical scoring tool that can accurately predict fatty liver disease in study volunteers, without the need for invasive tests (such as a tissue biopsy).

We aim to recruit initially 2000 volunteers to this study, both healthy volunteers and patients with known MASLD.

Volunteers will attend the unit to undergo all assessments on one day. Once consent is given with a study research physician, bloods will be taken and body measurements made (including BMI, weight, waist circumference). A full medical history and physical examination will then be performed by the research physician.

Bioimpedance body composition analysis will then be performed on an ACUNIQ device. Finally ultrasound of the liver and fibroscan will be performed. Once all assessments are complete the study volunteer will be discharged from the unit.

Once all results are finalised, analysis will be performed on all the data to create a clinical score to predict the presence of MASLD, both with statistical and machine learning methods.

Connect with a study center

  • Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge

    London, SE1 1YR
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.